MAURICIO CASTRO HERRERA

Allopathic & Osteopathic Physicians|Family Medicine ARKANSAS CITY, KS NPI 1982916565

General Payments — all program years on this page

$2,000.23

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 124
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $275.73 across 17 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $275.7317

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Acerta Pharma LLC $117.518
Novo Nordisk AS $53.253
Lilly USA, LLC $30.992
GlaxoSmithKline, LLC. $21.831
NOVARTIS PHARMACEUTICALS CORPORATION $19.121
PFIZER INC. $18.991
Insulet Corporation $14.041

By program year

Program yearAmountRecords
2018 $371.4127
2019 $227.7515
2020 $170.5812
2021 $415.2716
2022 $365.7125
2023 $173.7812
2024 $275.7317

Records — PY2024 (17)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1086914407 Novartis Pharmaceuticals Corporation $19.12 05/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096905987 Novo Nordisk Inc $17.99 09/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097738539 Novo Nordisk Inc $19.14 02/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097825405 Novo Nordisk Inc $16.12 03/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104213481 AstraZeneca Pharmaceuticals LP $14.58 09/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104388873 AstraZeneca Pharmaceuticals LP $15.70 01/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104438259 AstraZeneca Pharmaceuticals LP $13.27 09/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104554566 AstraZeneca Pharmaceuticals LP $14.26 02/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105245449 AstraZeneca Pharmaceuticals LP $15.04 10/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105593400 AstraZeneca Pharmaceuticals LP $15.04 06/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105788356 AstraZeneca Pharmaceuticals LP $15.04 11/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105801045 AstraZeneca Pharmaceuticals LP $14.58 08/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1115945183 GlaxoSmithKline, LLC. $21.83 02/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116810993 Insulet Corporation $14.04 07/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131430389 PFIZER INC. $18.99 11/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135185593 Lilly USA, LLC $17.73 04/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135202435 Lilly USA, LLC $13.26 04/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.